Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.40 |
| ▸ | PGK2 | P07205 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TPMT | P51580 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28629801 | 0.98 | PGK1 (0.39) | PGK1PGK2CA1CA2MMP1 | |
| SCHEMBL15367642 | 0.86 | SNCA (0.37) | PGK1PGK2CA1CA2MMP1 | |
| SCHEMBL24407435 | 0.82 | SLC22A12 (0.31) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL3894959 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KMT2AACLYACHE | |
| SCHEMBL2380439 | 0.78 | ALDH1A1 (0.39) | PGK1PGK2CA1CA2MMP1 | |
| SCHEMBL4878731 | 0.76 | CA1 (0.48) | PGK1PGK2CA1CA2MMP1 | |
| SCHEMBL1708798 | 0.76 | ALDH1A1 (0.39) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL2380436 | 0.76 | PGK1 (0.35) | PGK1PGK2CA1CA2MMP1 | |
| SCHEMBL14378208 | 0.76 | NR3C1 (0.39) | PGK1PGK2CA1CA2MMP1 | |
| SCHEMBL14399651 | 0.76 | RXRA (0.38) | CA2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102260246-B | Low-toxicity CB1 receptor inhibitor, preparation method thereof and application thereof in preparation of medicaments for drug abstention, weight reduction or diabetes treatment | FAN RULIN | 2014-08-13 | — | — | CN | claimed |
| CN-102603713-B | Chiral CB1 (cannabinoid) receptor inhibitor, and preparation method and medical application thereof | FAN RULIN | 2014-05-14 | — | — | CN | claimed |
| CN-102358735-B | Low toxicity multiple-point guided drug, nitrogen-containing aromatic ring CB1 receptor inhibitor with hydroxyl or substituted hydroxyl, and pharmaceutical use thereof | FAN RULIN | 2013-09-04 | — | — | CN | claimed |
| CN-103265517-A | 3-substituted coumarin derivative and use thereof | UNIV ZHEJIANG | 2013-08-28 | — | — | CN | claimed |
| CN-103265480-A | Quinolinedione derivative, and preparation method and use thereof | UNIV ZHEJIANG | 2013-08-28 | — | — | CN | claimed |
| CN-102260246-A | Low-toxicity CB1 receptor inhibitor, preparation method thereof and application thereof in preparation of medicaments for drug abstention, weight reduction or diabetes treatment | — | 2011-11-30 | — | — | CN | claimed |
| CN-102250006-A | 3-pyrazole carboxylic acid amide compounds, preparation method thereof and application thereof in preparation of medicines used as CB1 receptor inhibitors | RULIN FAN | 2011-11-23 | — | — | CN | claimed |
| CN-102212058-A | Single composite medicament (chiral nitrogenous heterocyclic ester) and synthesis method thereof as well as application of chiral nitrogenous heterocyclic ester in preparing low-toxicity CB1 receptor inhibitor | RULIN FAN | 2011-10-12 | — | — | CN | claimed |
| CN-116354897-B | Substituted 1,2, 4-triazole, pyridine and pyrimidine derivatives and application thereof in medicines | 华东师范大学 | 2024-10-15 | — | — | CN | disclosed |
| EP-3426246-B1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2024-05-01 | — | — | EP | disclosed |
| CN-116354897-A | Substituted 1,2, 4-triazole, pyridine and pyrimidine derivatives and application thereof in medicines | 华东师范大学 | 2023-06-30 | — | — | CN | disclosed |
| CN-111518095-A | Azaindole derivatives, and preparation method and application thereof | 华东师范大学 | 2020-08-11 | — | — | CN | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| EP-3426246-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | National Health Research Institutes (TW) | 2019-01-16 | — | — | EP | disclosed |
| CN-102358735-B | Low toxicity multiple-point guided drug, nitrogen-containing aromatic ring CB1 receptor inhibitor with hydroxyl or substituted hydroxyl, and pharmaceutical use thereof | FAN RULIN | 2013-09-04 | — | — | CN | disclosed |
| CN-103265517-A | 3-substituted coumarin derivative and use thereof | UNIV ZHEJIANG | 2013-08-28 | — | — | CN | disclosed |
| CN-103265480-A | Quinolinedione derivative, and preparation method and use thereof | UNIV ZHEJIANG | 2013-08-28 | — | — | CN | disclosed |
| CN-102260246-A | Low-toxicity CB1 receptor inhibitor, preparation method thereof and application thereof in preparation of medicaments for drug abstention, weight reduction or diabetes treatment | — | 2011-11-30 | — | — | CN | disclosed |
| CN-102250006-A | 3-pyrazole carboxylic acid amide compounds, preparation method thereof and application thereof in preparation of medicines used as CB1 receptor inhibitors | RULIN FAN | 2011-11-23 | — | — | CN | disclosed |
| CN-102212058-A | Single composite medicament (chiral nitrogenous heterocyclic ester) and synthesis method thereof as well as application of chiral nitrogenous heterocyclic ester in preparing low-toxicity CB1 receptor inhibitor | RULIN FAN | 2011-10-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544113-B2 | Thiazolidinone compounds and use thereof | OPRL1, OPRD1, OPRK1 | PGK1 3241/4885PGK2 2813/4885CA1 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.